5/9/2025

We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against the other stocks that will bounce back. Major US indexes finished in the green on Wednesday, May 7, after a volatile session […]

Source: Yahoo

5/7/2025

-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Three-Dose Immunization Series Expected in Mid-2026, With Complete Booster Data Up to Nine Months Later -- -- Company Expects to Initiate VAX-31 Adult Phase 3 Pivotal

Source: Yahoo

5/7/2025

For Q1 2025, the Fidelity Select Health Care Portfolio returned -1.03%, underperforming the MSCI health care index. Click here to read the full commentary.

Source: SeekingAlpha

5/6/2025

Last year’s pattern of large caps outperforming small caps has continued, although growth leadership has given way to value amid the preference for defense.

Source: SeekingAlpha

5/3/2025

The fund underperformed the Russell 3000 Growth Index benchmark in the first quarter of 2025.

Source: SeekingAlpha

5/1/2025

SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. “We are thrilled to welcome Olivier to Vaxcyte’s Board of Directors,” said Grant Pickering, Chief Ex

Source: Yahoo

4/30/2025

Insider-based indicators are finally approaching a level where market bottoms have formed. Click here to read more on what this signals to investors.

Source: SeekingAlpha

4/30/2025

We recently published a list of 11 Oversold NASDAQ Stocks to Buy Right Now. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against other oversold NASDAQ stocks to buy right now. On April 28, Darrell Cronk, Wells Fargo Wealth and Investment Management CIO, appeared on CNBC’s ‘Squawk […]

Source: Yahoo

4/16/2025

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Source: Yahoo

4/11/2025

We recently published a list of Billionaire Stanley Druckenmiller’s Top 10 Stocks Picks with Huge Upside Potential. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against Billionaire Stanley Druckenmiller’s other top stock picks with huge upside potential. Wall Street is overflowing with data. If companies are not […]

Source: Yahoo

4/10/2025

The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.

Source: Yahoo

4/7/2025

Source: SeekingAlpha

4/5/2025

Stay ahead in financial markets with Seeking Alpha's Wall Street Week Ahead as big banks are set to report earnings this week.

Source: SeekingAlpha

4/2/2025

VAXCYTE MISSION STATEMENT We are on a global mission to engineer high-fidelity vaccines that protect humankind from the consequences of bacterial diseases. ...

Source: Finnhub

4/1/2025

Evercore ISI notes that Vaxcyte (PCVX) missed four serotypes versus Prevnar20 in the “all-important” infant data, adding that an “imperfect vaccine press release on the heels of Peter Marks resignation is just tough timing.” However, the analyst contends that three of the four misses in today’s Phase 2 are “narrow – and will quite likely be ok” in a larger Phase 3 trial. The firm maintains an Outperform rating on Vaxcyte shares, which are down $34.89, or 50%, to $34.57 in early afternoon trading

Source: Yahoo

4/1/2025

The major averages were mostly lower near noon, with the Dow up fractionally but the Nasdaq down nearly 250 points amid mounting concerns about President Donald Trump’s upcoming announcement of promised new tariffs. Meanwhile, the S&P 500’s early losses brought the index to its lowest level since September. Looking to commodities, gold prices are sharply higher, continuing their rally to over $3,150, while oil prices are also up over 2.5%. Get caught up quickly on the top news and calls moving s

Source: Yahoo

4/1/2025

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.

Source: Yahoo

4/1/2025

Vaxcyte is awaiting data from another candidate before advancing to Phase III.

Source: Yahoo

3/31/2025

Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays impact it. Click for my PCVX update.

Source: SeekingAlpha

3/31/2025

Biotech stocks were hammered Monday after Peter Marks, a top FDA official, resigned amid a clash with Robert F. Kennedy Jr.

Source: Yahoo